Results 111 to 120 of about 50,217 (224)

Hazelnut and Walnut Vicilins in Tree Nut Allergy: Co‐Sensitization Patterns and Clinical Severity Associations

Allergy, EarlyView.
This observational analysis of a consecutive tertiary‐care cohort included 70 patients with walnut allergy and 44 patients with hazelnut allergy. Clinical severity was classified as mild, moderate, or severe. Hazelnut and walnut allergy severity was better captured by molecule‐specific IgE profiles than by undifferentiated seed storage protein ...
Danilo Villalta, Giulia Marcassa, Gabriella Cusa, Mariaelisabetta Conte, Francesca Buzzulini, Bo Pontoppidan, Elisabetta Caprini, Jonas Östling, Lars Mattsson, Marie Holmqvist, Mauro Giani, Lorenzo Cecchi, Riccardo Asero, Jonas Lidholm, Enrico Scala   +14 more
wiley   +1 more source

Urticaria: An update on pathophysiology, diagnosis, and management

Tungs’ Medical Journal
Urticaria is a relatively common clinical skin disorder, and the condition is an inflammatory allergic immune response in the skin mucosa which increases the permeability of the subcutaneous capillaries.
Chieh Chen, Da-Ming Liao
doaj   +1 more source

Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy

Allergy, EarlyView.
We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov, Maria G. Byazrova, Evgenii V. Smolnikov, Vladislav N. Turenko, Valeriy V. Smirnov, Igor P. Shilovskii, Nadezhda N. Shershakova, Ekaterina N. Medunitsyna, Olga G. Elisyutina, Mikhail V. Pashenkov, George B. Pasikhov, Vladimir V. Murugin, Veronika A. Parshina, Darya K. Bolyakina, Anastasia S. Primak, Mariya A. Lapyko, Inna V. Danilycheva, Rosalia V. Schubelko, Anastasia A. Tsyvkina, Nataliia V. Shartanova, Daria O. Timoshenko, Irina I. Isakova, Tatiana V. Latysheva, Andrey E. Shulzhenko, Elena A. Latysheva, Oksana M. Kurbacheva, Elena S. Fedenko, Oksana A. Markova, Ilya A. Korotkevich, Violetta V. Yan, Natalia A. Gavrilova, Mariia V. Tikhomirova, Ivan V. Shevchenko, Alena A. Agafonova, Gregory N. Poroshin, Dmitry A. Kudlay, Alexander V. Filatov, Evgeniya V. Nazarova, Daria S. Kruchko, Dmitriy V. Goryachev, Vadim A. Merkulov, Nataliya I. Ilina, Rudolf Valenta, Veronica I. Skvortsova   +43 more
wiley   +1 more source

Eosinophils Play a Surprising Leading Role in Recurrent Urticaria in Horses

Vaccines
Urticaria, independent of or associated with allergies, is commonly seen in horses and often shows a high reoccurrence rate. Managing these horses is discouraging, and efficient treatment options are lacking.
Katharina Birkmann, Fadi Jebbawi, Nina Waldern, Sophie Hug, Victoria Inversini, Giulia Keller, Anja Holm, Paula Grest, Fabia Canonica, Peter Schmid-Grendelmeier, Antonia Fettelschoss-Gabriel   +10 more
doaj   +1 more source

IgE‐Binding Bacterial Components Not Yet Documented in the Allergen Databases and Their Allergenic Mechanisms: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Among bacteria that are associated with the development and/or exacerbation of allergic/atopic diseases, several have been described to produce IgE‐binding components. However, only one bacterial protein, Bac s 1, is currently listed in the official database of the World Health Organization/International Union of Immunological Societies (WHO ...
Uta Jappe, Marua Abu Risha, Ioana Agache, Claus Bachert, Barbara Bröker, Riccardo Castagnoli, Gabriele Gadermaier, Richard E. Goodman, Amir Guemari, Christiane Hilger, Alain Jacquet, Sabine Kespohl, Ludger Klimek, Annette Kuehn, Jonas Lidholm, Vera Mahler, Markus Ollert, Thomas A. Platts‐Mills, Monika Raulf, Peter Schmid‐Grendelmeier, Frieder Schmiedeke, Marianne van Hage, Joana Vitte, Josefina Zakzuk, Anna Pomés   +24 more
wiley   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Relato de caso: Urticária induzida por exercício físico resistido em pacientes com tireoidite de hashimoto [PDF]

Resumo: Este relato de caso descreve um paciente adolescente, portador de doença autoimune (tireoidite de Hashimoto), que apresentou episódios de urticária severa e reações alérgicas após a prática específica de musculação. O quadro clínico incluiu edema
Arruda, Jalsi Tacon, Filho, Cesar Taia, Lorencetti Giombelli, Luiz Antônio, França, Ricardo Cintra, Romero dos Santos, Bryan Henrique, Melo, Henrique   +5 more
core   +1 more source

Dupilumab in Cholinergic Urticaria: An Exploratory Phase 2 Investigator‐Initiated Study

Allergy, EarlyView.
Annika Gutsche, Weronika Grabowska, Sabine Altrichter, Eva Grekowitz, Stephanie Roll, Guido Heine, Petra Staubach, Wolfgang Pfützner, Randolf Brehler, Andrea Bauer, Nicola Wagner, Gerda Wurpts, Pascale Salameh, Ali Salehzadeh‐Yazdi, Samad S. Jahandideh, Martin Metz   +15 more
wiley   +1 more source

Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy

Allergy, EarlyView.
In this Phase 2a trial, severely peanut‐allergic participants were randomized to abatacept versus placebo with peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. No significant difference was observed for the primary efficacy outcome (the relative change from baseline in peanut‐specific/total IgE ratio at 24 weeks), but ...
Marie‐Lee Simard, Camille Braun, Éloise Antony, Émilie Roy, Marie‐Ève Gingras, François Graham, Anne Des Roches, Louis Paradis, Kathryn Samaan, Florence Gingras‐Lessard, Roxane Labrosse, Thomas Eiwegger, Philippe Bégin   +12 more
wiley   +1 more source

Safety and Clinical Outcomes of High‐ Versus Low‐Dose Oral Peanut Immunotherapy in Polish Children With Peanut Allergy

Acta Paediatrica, EarlyView.
ABSTRACT Aim To compare safety and clinical outcomes of two different oral immunotherapy (OIT) maintenance doses (150 mg vs. 300 mg) of peanut protein in children with peanut allergy. Methods This prospective study enrolled 44 children aged 4–17 years with confirmed peanut allergy.
Klementyna Łyżwa, Magdalena Chojnowska‐Wójtowicz, Wioletta Zagórska, Marek Kulus, Katarzyna Grzela   +4 more
wiley   +1 more source